Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 14/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4293076 | 1.00 | TRPA1 (0.68) | TRPA1SIGMAR1ABCB11GABRA1MAPT | |
| SCHEMBL4293078 | 1.00 | TRPA1 (0.68) | TRPA1SIGMAR1ABCB11GABRA1MAPT | |
| SCHEMBL3667051 | 0.87 | TRPA1 (0.66) | TRPA1SIGMAR1ABCB11GABRA1MAPT | |
| SCHEMBL4297061 | 0.87 | TRPA1 (0.66) | TRPA1SIGMAR1ABCB11GABRA1MAPT | |
| SCHEMBL3667048 | 0.87 | TRPA1 (0.66) | TRPA1SIGMAR1ABCB11GABRA1MAPT | |
| SCHEMBL3667053 | 0.87 | TRPA1 (0.66) | TRPA1SIGMAR1ABCB11GABRA1MAPT | |
| SCHEMBL4448485 | 0.81 | TRPA1 (1.00) | TRPA1SIGMAR1ABCB11GABRA1MAPT | |
| SCHEMBL1499481 | 0.81 | TRPA1 (1.00) | TRPA1SIGMAR1ABCB11GABRA1MAPT | |
| SCHEMBL1499480 | 0.81 | TRPA1 (1.00) | TRPA1SIGMAR1ABCB11GABRA1MAPT | |
| SCHEMBL3668616 | 0.75 | TRPA1 (0.61) | TRPA1SIGMAR1ABCB11MAPTCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751850-B2 | TRPA1 antagonists | ABBVIE INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20150065538-A1 | TRPA1 ANTAGONISTS | ABBVIE INC (US) | 2015-03-05 | — | — | US | disclosed |
| US-8877784-B2 | TRPA1 antagonists | ABBVIE INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20090264480-A1 | TRPA1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065538-A1 | TRPA1 ANTAGONISTS | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885SIGMAR1 266/4885ABCB11 700/4885 |
| US-20090264480-A1 | TRPA1 ANTAGONISTS | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885SIGMAR1 266/4885ABCB11 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.